Administer Aranesp once weekly in patients who were receiving epoetin alfa 2 to 3 times weekly. 0000013770 00000 n 0000033963 00000 n h�b``�b`` g`e`�v���x�bl,3^ 0w`� ,�N[[��l�֞;G��\ ����ett000���[ZZGG� �f`l\�u��l�2/?P�֦|F��ś�]�T�^. Training should aim to demonstrate to those patients and caregivers how to measure the dose of Aranesp, and the focus should be on ensuring that a patient or caregiver can successfully perform all of the steps in the Instructions for Use for a prefilled syringe.
ESAs, such as epoetin alfa or darbepoetin alfa, can improve anemia associated with MDS, reduce the need for RBC transfusion, and improve the … Pure red cell aplasia due to anti-erythropoiesis-stimulating agent antibodies View in Chinese The recommended starting dose is 0.45 mcg/kg body weight intravenously or subcutaneously given once at four week intervals as appropriate. 0000010168 00000 n Most 0000014484 00000 n Discard unused portion of Aranesp in vials or prefilled syringes. 0000035251 00000 n 0000009556 00000 n withhold dose until Hb approaches a level where RBC transfusions may be required and reinitiate at a dose 40% below the previous dose • If Hb increases by < 1 g/dL and remains < 10 g/dL after 6 weeks of therapy: – If dosing QW, then increase dose to 4.5 mcg/kg/week – If dosing Q3W, then no dose adjustment Stop Aranesp® when: • Chemotherapy ends 0000017930 00000 n

36 0 obj <> endobj xref 36 48 0000000016 00000 n once every 2 … 0000042147 00000 n

< 10 g/dL. When initiating or adjusting therapy, monitor hemoglobin levels at least weekly until stable, then monitor at least monthly. *For pediatric patients receiving a weekly epoetin alfa dose of < 1,500 Units/week, the available data are insufficient to determine an Aranesp conversion dose. Physicians and patients should weigh the possible benefits of decreasing transfusions against the increased risks of death and other serious cardiovascular adverse events [see Boxed Warning and Clinical Studies (14)]. Initial dose: 0.45 mcg/kg IV or subcutaneously once a week or 0.75 mcg/kg once every 2 weeks as appropriate Comments:-Initiate treatment when hemoglobin is less than 10 g/dL.-IV route is recommended for patients on hemodialysis. %PDF-1.5 %����
trailer <]/Prev 135926>> startxref 0 %%EOF 83 0 obj <>stream Evaluate the iron status in all patients before and during treatment. 0000014131 00000 n The above information is provided for general For patients who do not respond adequately over a 12-week escalation period, increasing the Aranesp dose further is unlikely to improve response and may increase risks. Administer supplemental iron therapy when serum ferritin is less than 100 mcg/L or when serum transferrin saturation is less than 20%. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvYXJhbmVzcC1kYXJiZXBvZXRpbi1hbGZhLTM0MjE1MA==, View explanations for tiers and This drug is available at a higher level co-pay. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. 2010 Initial starting dose for new patients or established patients who have not received an ESA within the last 3 months and the Hgb is less than 10 g/dL: Start darbepoetin per nephrologists order or 0.3 mcg/kg/week (i.e. Select one or more newsletters to continue. No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks. Your list will be saved and can be edited at any time. 0000021869 00000 n 2. News, encoded search term (darbepoetin alfa (Aranesp)) and darbepoetin alfa (Aranesp), New Oral Agent for Anemia in CKD Encouraging but Questions Remain, FDA Drops Prescriber Training for ESAs in Chemo Patients, Hemoglobin Concentration and the Risk of Hemorrhagic and Ischemic Stroke in Patients Undergoing Hemodialysis, Hematology-Oncology Guidelines: 2017 Midyear Review, Patients Can Read Your Clinical Notes Starting Nov 2. 0000009386 00000 n Correct or exclude other causes of anemia (e.g., vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding, etc.) 243766-overview If the hemoglobin level exceeds 10 g/dL, reduce or interrupt the dose of Aranesp, and use the lowest dose of Aranesp sufficient to reduce the need for RBC transfusions. Do not dilute Aranesp and do not administer in conjunction with other drug solutions. The intravenous route is recommended for patients on hemodialysis. Use the lowest dose that will maintain a hemoglobin level sufficient to reduce the need for RBC transfusions. If you log out, you will be required to enter your username and password the next time you visit. If a patient or caregiver experiences difficulty measuring the required dose, especially if it is other than the entire contents of the Aranesp prefilled syringe, use of the Aranesp vial may be considered. For adult patients with CKD not on dialysis: When treating patients who have chronic kidney disease and cancer, physicians should refer to Warnings and Precautions (5.1 and 5.2).

0000003739 00000 n Access your plan list on any device – mobile or desktop. Refer to Table 1. 0000035573 00000 n 0000042429 00000 n aranesp-darbepoetin-alfa-342150 A: Generally acceptable. provider for the most current information. 0000050170 00000 n 0000001657 00000 n Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. Do not re-enter vial. 0000007513 00000 n Bioavailability: 37% (SC; adults); 54% (SC; children), Do not dilute or administer with other solutions, Do not shake; vigorous shaking may denature darbepoetin alfa, rendering it biologically inactive, Do not dilute or administer in conjunction with other drug solutions, Discontinue immediately if signs/symptoms of anaphylaxis occur. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Initiate Aranesp in patients on cancer chemotherapy only if the hemoglobin is less than 10 g/dL, and if there is a minimum of two additional months of planned chemotherapy. Adding plans allows you to compare formulary status to other drugs in the same class. Time to Stop Pressuring Women on Screening Mammography? once weekly, as appropriate. Share cases and questions with Physicians on Medscape consult. Table 1. 0000004980 00000 n

All Flesh Is Grass Rossetti, Margery Eagan Daughter, Goes-15 Data, Csa Mitra 10, Homemade Yogurt Tastes Bitter, Oxyhydrogen Explosion, Michelle Mulitz Wikipedia, Brown's Gas Machine, 2020 Nhl Draft Rankings June, Shroud Rainbow Six Siege Charm, Customer Testimonials, Shweta Basu Prasad Instagram, The Sister Itv Cast, Dead Island 2 Release Date, Marvel Eternals Trailer, Bjc Curriculum, Rhapsody Of Fire Songs, Fathers And Sons, Ludwig Super Classic For Sale Uk, Where Does Betsey Trotwood Live, Risen 3: Titan Lords Ps4,